EUVIMEDEUVIMED entdecken
Crossref

Facial Amphiphile-Modified Lipids Highly Sensitize Liposomes toward Secretory Phospholipase A 2

Yanjiao Liu, Xingang Yao iD, Cheng Wen, Dan Li, Jiawen Zhang, Baomin Xi, Brian S Cummings, Guodong Zhu iD

Molecular Pharmaceutics · 2024

DOI: 10.1021/acs.molpharmaceut.4c00271 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Yanjiao Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy and Food Engineering, Wuyi University, Jiangmen, Guangdong 529020, People's Republic of China. Hauptthemen laut MEDLINE: Liposomes, Phospholipases A2, Secretory, Oxaliplatin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Wuyi University-Macau University Joint Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Upregulated secretory phospholipase A2 (sPLA2) in tumors has been proposed as a stimulus to trigger drug release from liposomes for therapeutic effects. However, the current strategy for developing sPLA2-responsive liposomes merely considering substrate preference suffers from limited membrane disruptive effects induced by enzymatic hydrolysis and safety issues resulting from the overuse of sPLA2-preferred lipids. Here, a membrane-destabilizing mechanism based on enzymatic extraction and the transition of facial amphiphiles (FAs) within lipid membranes was introduced. Enzymatic degradation of FA-modified lipids, a process involving substrate extraction of lipids from membranes and cleavage of sn-2 ester bonds by sPLA2, rotation, and interface settling of detached FAs, caused tremendous efflux of payloads from liposomes, termed the SECRIS effect. In the presence of sPLA2, oxaliplatin (L-OHP) loaded liposomes containing FA-modified lipids showed enhanced drug release, comparable in vitro cytotoxicity, and excellent in vivo antitumor efficacy and reduced adverse syndromes in Colo205-bearing mice compared to conventional sPLA2-labile formulations. The discovery of the SECRIS effect creates a new pathway to engineer liposome platforms for the treatment of sPLA2-positive tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LiposomesPhospholipases A2, SecretoryOxaliplatinAnimalsMiceHumansCell Line, TumorDrug LiberationAntineoplastic AgentsLipidsXenograft Model Antitumor AssaysMice, Inbred BALB CFemaleColonic Neoplasms

Stichwörter der Autor:innen

chemotherapydrug deliveryenzyme-responsive nanoparticlefacial amphiphileliposomeplatinum drugsecretory phospholipase A2tumor microenvironment

Substanzen

LiposomesPhospholipases A2, SecretoryOxaliplatinAntineoplastic AgentsLipids

Autor:innen und Institutionen

  • School of Pharmacy and Food Engineering, Wuyi University, Jiangmen, Guangdong 529020, People's Republic of China.
  • School of Pharmacy, Southern Medical University, Guangzhou, Guangdong 510515, People's Republic of China.
  • Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan 48201, United States.

ORCID-Profile: Xingang Yao, Guodong Zhu

Förderung

  • National Natural Science Foundation of China
  • Wuyi University-Macau University Joint Research Fund

Zitieren

APA

Liu, Y., Yao, X., Wen, C., Li, D., Zhang, J., Xi, B., Cummings, B. S., & Zhu, G. (2024). Facial Amphiphile-Modified Lipids Highly Sensitize Liposomes toward Secretory Phospholipase A 2. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00271

Vancouver

Liu Y, Yao X, Wen C, Li D, Zhang J, Xi B, et al. Facial Amphiphile-Modified Lipids Highly Sensitize Liposomes toward Secretory Phospholipase A 2. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.4c00271

BibTeX
@article{Liu2024,
  author = {Liu, Yanjiao and Yao, Xingang and Wen, Cheng and Li, Dan and Zhang, Jiawen and Xi, Baomin and Cummings, Brian S and Zhu, Guodong},
  title = {Facial Amphiphile-Modified Lipids Highly Sensitize Liposomes toward Secretory Phospholipase A 2},
  journal = {Molecular Pharmaceutics},
  year = {2024},
  doi = {10.1021/acs.molpharmaceut.4c00271}
}
Kostenlos starten →